Demographic and clinical characteristics of study participants used for detection of CXCL4 and CXCL7 by immunofluorescence
| Resolving arthritis | Early RA | Established RA | Early non-RA | |
|---|---|---|---|---|
| Number | 9 | 10 | 11 | 5 |
| Symptom duration (weeks); median (IQR) | 6 (3–7) | 7 (4.8–9.3) | 45 (16–53) | 7 (2–8.5) |
| Female; n (%) | 3 (33) | 5 (50) | 6 (55) | 2 (40) |
| Age, years; median (IQR) | 37 (33–65) | 58 (50–65) | 62 (57–65) | 41 (37–56) |
| RF and/or anti-CCP positive; n (%) | 0 (0) | 4 (40) | 6 (55) | 1 (20) |
| Global disease-related variables | ||||
| CRP; median (IQR) | 8 (3–13.5) | 26 (7.5–58) | 10 (0–79) | 25 (18.5–54) |
| ESR; median (IQR) | 18 (5.5–51) | 19 (4.75–39.25) | 50 (34–70) | 44 (24–73.5) |
| DAS28; median (IQR) | 4.1 (3.4–5.7) | 4.7 (3.8–5.8) | 5.2 (4.6–7.5) | 4.8 (4.1–6.4) |
| Biopsied joint-related variables | ||||
| Joint biopsied | ||||
| Ankle; n (%) | 2 (22) | 2 (20) | 3 (27) | 2 (40) |
| Knee; n (%) | 7 (78) | 7 (70) | 8 (73) | 3 (60) |
| MCP joint; n (%) | 0 (0) | 1 (10) | 0 (0) | 0 (0) |
Early non-RA group: psoriatic arthritis n=2, sarcoidosis n=1, ankylosing spondylitis n=1, unclassified n=1.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available; RF, rheumatoid factor.